363250 — Genesystem Co Cashflow Statement
0.000.00%
- KR₩59bn
- KR₩51bn
- KR₩897m
Annual cashflow statement for Genesystem Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4,041 | -2,224 | 3,551 | -8,996 | -8,059 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 2,184 | 6,485 | -638 | 3,469 | -80.3 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -371 | -814 | -2,235 | -1,276 | -218 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2,093 | 3,697 | 986 | -6,417 | -7,812 |
Capital Expenditures | -298 | -5,783 | -798 | -325 | -419 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 10.2 | 21.2 | -12,103 | -2,239 | 333 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -288 | -5,761 | -12,901 | -2,565 | -85.4 |
Financing Cash Flow Items | 10 | 16.8 | -1,763 | 28.3 | 24.1 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -29.2 | 11,062 | 27,854 | 181 | 178 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2,411 | 8,256 | 16,573 | -8,794 | -7,747 |